Clinical trial
Efficacy and Safety of Artificial Saliva Containing Cumin and Ginger Extract in Hemodialysis
Name
0763/66
Description
Hemodialysis patients with xerostomia are divided into 2 groups which are group A (start with artificial saliva containing cumin and ginger extract for 2 weeks, free periods 2 weeks, then placebo for 2 weeks) and group B (start with placebo for 2 weeks, free periods 2 weeks, then artificial saliva containing cumin and ginger extract for 2 weeks). Amount of saliva (g/min), xerostomia's questionnair, Increase of saliva score, WHO Oral Mucositis Grading Scale, pH of saliva, quality of life's questionnair will measure before, after using the sample for 7 and 14 days.
Trial arms
Trial start
2024-07-01
Estimated PCD
2024-12-30
Trial end
2025-01-31
Status
Not yet recruiting
Treatment
Artificial saliva containing cumin and ginger extract
The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Arms:
Artificial saliva containing cumin and ginger extract
Placebo
The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Arms:
Placebo
Size
26
Primary endpoint
Xerostomia score
14 days
Eligibility criteria
Inclusion Criteria:
* Age more than 18 years
* Hemodialysis patients with xerostomia (saliva flow rate less than 0.2 g/min)
* Hemodialysed history more than 3 months
* Be willing to participate in the study
Exclusion Criteria:
* Patients with sialolith or Sjogren's syndrome
* Uncontrolled other diseases
* Using artificial saliva for more than 2 weeks
* Taking pilocarpine and cevimeline
* Allergic to ginger, cumin, xylitol, and glycerin
* Have mucositis
* Pregnancy or lactation
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 26, 'type': 'ESTIMATED'}}
Updated at
2024-06-26
1 organization
1 product
1 drug
1 indication
Organization
Chulalongkorn UniversityIndication
Dry MouthDrug
Varlilumab